CYP3A

CYP3A enzymes are major members of the cytochrome P450 superfamily and catalyze the oxidative metabolism of endogenous compounds, xenobiotics, and a substantial proportion of clinically used drugs^[1][2]. CYP3A4 is the predominant hepatic and intestinal isoform and is responsible for the metabolism of approximately 30-50% of marketed medications, making it a central determinant of drug disposition and drug-drug interactions^[1][2]. Mechanistically, CYP3A expression is regulated through transcriptional networks involving the pregnane X receptor (PXR), hepatocyte nuclear factor 4α (HNF4α), constitutive androstane receptor (CAR), and vitamin D receptor (VDR), which coordinate xenobiotic sensing and detoxification pathways^[1]. In disease and pharmacological models, altered CYP3A activity contributes to inter-individual variability in drug exposure and therapeutic response, highlighting its importance in precision medicine and clinical pharmacology research^[1]. Compared with related isoforms, CYP3A4 is the most abundant drug-metabolizing enzyme in adult liver, whereas CYP3A5 displays distinct tissue distribution and contributes substantially to extrahepatic metabolism, supporting isoform-specific effects on substrate clearance and pharmacokinetics^[2][3]. For experimental applications, selective inhibition of CYP3A activity remains a standard approach for evaluating metabolic pathways and drug-drug interaction risk, with ketoconazole serving as a widely used CYP3A inhibitor in human liver microsomes and recombinant CYP3A4/5 systems^[3][4]. Therefore, CYP3A enzymes represent critical targets for mechanistic studies of xenobiotic metabolism, pharmacogenomics, and therapeutic optimization^[1][2].